proxyvotesnow.com

Home › Companies › ARBUTUS BIOPHARMA CORP. › 2024-2025

ARBUTUS BIOPHARMA CORP. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and ARBUTUS BIOPHARMA CORP.’s Form 8-K, filed 2025-05-23 (Item 5.07 on EDGAR). Page generated 04 October 2026.

  • 9Reported items
  • 137Asset managers
  • 1,038Fund votes
  • 2025-05-21Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ARBUTUS BIOPHARMA CORP. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by ARBUTUS BIOPHARMA CORP.

These tallies are ARBUTUS BIOPHARMA CORP.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-05-23 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ARBUTUS BIOPHARMA CORP. — official shareholder meeting results, meeting held 2025-05-21
Ballot itemForAgainst AbstainWithheldBroker non-votesOutcome
Elect Director: Lindsay Androski, JD, MBA, CFA 123,784,223---- 6,331,63428,231,130 Majority: yes
Elect Director: Robert Alan Beardsley 124,837,983---- 5,277,87428,231,130 Majority: yes
Elect Director: Joseph Bishop 122,059,590---- 8,056,26728,231,130 Majority: yes
Elect Director: Matthew Gline 122,656,045---- 7,459,81228,231,130 Majority: yes
Elect Director: Anuj Hasija 124,821,361---- 5,294,49628,231,130 Majority: yes

Source: ARBUTUS BIOPHARMA CORP., Form 8-K, filed with the SEC on 2025-05-23 — read the filing on EDGAR.

How asset managers voted at the ARBUTUS BIOPHARMA CORP. 2024-2025 meeting

Each item below shows how the 137 asset managers that disclosed a ARBUTUS BIOPHARMA CORP. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ARBUTUS BIOPHARMA CORP.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the Proxy Statement/Circular; and

SECTION 14A SAY-ON-PAY VOTES

Combines 4 wordings of this item as funds reported it.

98% fund support · no official result

FOR 98%

The 130 asset managers below cast 98% of the shares they voted on this item FOR (77,580,901 for, 1,346,256 against).

FOR: 77,580,901 (98.3%)AGAINST: 1,346,256 (1.7%)ABSTAIN: 1,824 (0.0%)
Largest asset managers voting on “To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in ” at ARBUTUS BIOPHARMA CORP., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Morgan Stanley29,050,2230 00For
Two Seas Capital LP9,272,5550 00For
Vanguard9,111,5190 00For
BlackRock8,491,97054,827 00For
State Street2,798,9481,481 00For
Woodline Partners LP2,552,9420 00For
Charles Schwab2,392,6240 00For
Fidelity2,263,7830 00For
GEODE CAPITAL MANAGEMENT, LLC2,195,7110 00For
Equitable1,452,5240 00For
Rangeley Capital, LLC1,349,0000 00For
Rubric Capital Management LP827,3280 00For
Northern Trust799,5750 00For
Aberdeen0684,758 00Against
Hudson Bay Capital Management LP484,4610 00For
ADAR1 Capital Management, LLC454,9200 00For
Wellington370,5380 00For
Nuveen313,3070 00For
TIAA311,1730 00For
PARAMETRIC PORTFOLIO ASSOCIATES LLC294,7580 00For
UBS0267,277 00Against
MELLON INVESTMENTS Corp214,0290 00For
Saba Capital Income & Opportunities Fund188,51020,341 1,0170For
Lincoln Financial195,5760 00For
KENNEDY CAPITAL MANAGEMENT LLC147,86033,734 00For

Showing the 25 largest of 130 asset managers. See all 130 in the interactive database.

2. To approve the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.

AUDIT-RELATED

99.9% fund support · no official result

FOR 99.9%

The 38 asset managers below cast 99.9% of the shares they voted on this item FOR (28,209,799 for, 1,081 against).

FOR: 28,209,799 (100.0%)AGAINST: 1,081 (0.0%)ABSTAIN: 148 (0.0%)
Largest asset managers voting on “To approve the appointment of Ernst & Young LLP as our independent registered public accounting firm for the f” at ARBUTUS BIOPHARMA CORP., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard8,631,0060 00For
Morgan Stanley6,930,2430 00For
BlackRock5,196,3830 00For
Fidelity2,236,8420 00For
Equitable1,452,5240 00For
Charles Schwab1,196,1920 00For
State Street643,5800 00For
Aberdeen342,3790 00For
TIAA311,1730 00For
Saba Capital Income & Opportunities Fund209,082692 950For
Lincoln Financial195,5760 00For
Saba Capital Income & Opportunities Fund II117,464389 530For
Global X87,2170 00For
Goldman Sachs76,1520 00For
Northern Trust75,3330 00For
ProShares59,3470 00For
John Hancock55,6370 00For
Pacific Life48,2210 00For
ETFis Series Trust I43,2090 00For
Voya40,7200 00For
Invesco34,9970 00For
Direxion Shares ETF Trust32,5530 00For
Bridge Builder Trust32,1230 00For
DWS21,1530 00For
QUANTITATIVE MASTER SERIES LLC21,0610 00For

Showing the 25 largest of 38 asset managers. See all 38 in the interactive database.

3. To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Anuj Hasija

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 124,821,361WITHHELD: 5,294,496

ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Anuj Hasija”): 124,821,361 for, 5,294,496 withheld, per its Form 8-K filed 2025-05-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 191,527,129 outstanding shares: 65% for, 3% withheld (68% of the company cast a for/withheld vote).

The 36 asset managers below cast 100% of the shares they voted on this item FOR (27,883,253 for, 0 against).

FOR 100%
FOR: 27,883,253 (100.0%)
Largest asset managers voting on “To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual” at ARBUTUS BIOPHARMA CORP., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard8,631,0060 00For
Morgan Stanley6,930,2430 00For
BlackRock5,196,3830 00For
Fidelity2,236,8420 00For
Equitable1,452,5240 00For
Charles Schwab1,196,1920 00For
State Street643,5800 00For
Aberdeen342,3790 00For
TIAA311,1730 00For
Lincoln Financial195,5760 00For
Global X87,2170 00For
Goldman Sachs76,1520 00For
Northern Trust75,3330 00For
ProShares59,3470 00For
John Hancock55,6370 00For
Pacific Life48,2210 00For
ETFis Series Trust I43,2090 00For
Voya40,7200 00For
Invesco34,9970 00For
Direxion Shares ETF Trust32,5530 00For
Bridge Builder Trust32,1230 00For
DWS21,1530 00For
QUANTITATIVE MASTER SERIES LLC21,0610 00For
Nationwide21,0490 00For
Columbia Threadneedle17,8010 00For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

4. To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Joseph Bishop

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 122,059,590WITHHELD: 8,056,267

ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Joseph Bishop”): 122,059,590 for, 8,056,267 withheld, per its Form 8-K filed 2025-05-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 191,527,129 outstanding shares: 64% for, 4% withheld (68% of the company cast a for/withheld vote).

The 36 asset managers below cast 100% of the shares they voted on this item FOR (26,569,049 for, 0 against).

FOR 95%
FOR: 26,569,049 (95.3%)ABSTAIN: 1,314,204 (4.7%)
Largest asset managers voting on “To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual” at ARBUTUS BIOPHARMA CORP., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard8,631,0060 00For
Morgan Stanley6,930,2430 00For
BlackRock5,196,3830 00For
Fidelity2,222,7470 14,0950For
Equitable1,452,5240 00For
Charles Schwab00 1,196,1920Abstain
State Street643,5800 00For
Aberdeen342,3790 00For
TIAA311,1730 00For
Lincoln Financial195,5760 00For
Global X00 87,2170Abstain
Goldman Sachs76,1520 00For
Northern Trust75,3330 00For
ProShares59,3470 00For
John Hancock55,6370 00For
Pacific Life48,2210 00For
ETFis Series Trust I43,2090 00For
Voya40,7200 00For
Invesco34,9970 00For
Direxion Shares ETF Trust32,5530 00For
Bridge Builder Trust32,1230 00For
DWS21,1530 00For
QUANTITATIVE MASTER SERIES LLC21,0610 00For
Nationwide21,0490 00For
Columbia Threadneedle17,8010 00For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

5. To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Lindsay Androski, JD, MBA, CFA

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 123,784,223WITHHELD: 6,331,634

ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Lindsay Androski, JD, MBA, CFA”): 123,784,223 for, 6,331,634 withheld, per its Form 8-K filed 2025-05-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 191,527,129 outstanding shares: 65% for, 3% withheld (68% of the company cast a for/withheld vote).

The 36 asset managers below cast 100% of the shares they voted on this item FOR (27,841,928 for, 0 against).

FOR 99.8%
FOR: 27,841,928 (99.9%)ABSTAIN: 41,325 (0.1%)
Largest asset managers voting on “To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual” at ARBUTUS BIOPHARMA CORP., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard8,631,0060 00For
Morgan Stanley6,930,2430 00For
BlackRock5,196,3830 00For
Fidelity2,236,8420 00For
Equitable1,452,5240 00For
Charles Schwab1,196,1920 00For
State Street643,5800 00For
Aberdeen342,3790 00For
TIAA311,1730 00For
Lincoln Financial195,5760 00For
Global X87,2170 00For
Goldman Sachs76,1520 00For
Northern Trust75,3330 00For
ProShares59,3470 00For
John Hancock55,6370 00For
Pacific Life48,2210 00For
ETFis Series Trust I43,2090 00For
Voya00 40,7200Abstain
Invesco34,9970 00For
Direxion Shares ETF Trust32,5530 00For
Bridge Builder Trust32,1230 00For
DWS21,1530 00For
QUANTITATIVE MASTER SERIES LLC21,0610 00For
Nationwide21,0490 00For
Columbia Threadneedle17,8010 00For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

6. To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Matthew Gline

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%
FOR: 122,656,045WITHHELD: 7,459,812

ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Matthew Gline”): 122,656,045 for, 7,459,812 withheld, per its Form 8-K filed 2025-05-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 191,527,129 outstanding shares: 64% for, 4% withheld (68% of the company cast a for/withheld vote).

The 36 asset managers below cast 100% of the shares they voted on this item FOR (26,569,049 for, 0 against).

FOR 95%
FOR: 26,569,049 (95.3%)ABSTAIN: 1,314,204 (4.7%)
Largest asset managers voting on “To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual” at ARBUTUS BIOPHARMA CORP., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard8,631,0060 00For
Morgan Stanley6,930,2430 00For
BlackRock5,196,3830 00For
Fidelity2,222,7470 14,0950For
Equitable1,452,5240 00For
Charles Schwab00 1,196,1920Abstain
State Street643,5800 00For
Aberdeen342,3790 00For
TIAA311,1730 00For
Lincoln Financial195,5760 00For
Global X00 87,2170Abstain
Goldman Sachs76,1520 00For
Northern Trust75,3330 00For
ProShares59,3470 00For
John Hancock55,6370 00For
Pacific Life48,2210 00For
ETFis Series Trust I43,2090 00For
Voya40,7200 00For
Invesco34,9970 00For
Direxion Shares ETF Trust32,5530 00For
Bridge Builder Trust32,1230 00For
DWS21,1530 00For
QUANTITATIVE MASTER SERIES LLC21,0610 00For
Nationwide21,0490 00For
Columbia Threadneedle17,8010 00For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

7. To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed: Robert Alan Beardsley

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 124,837,983WITHHELD: 5,277,874

ARBUTUS BIOPHARMA CORP.’s own tally for this item (“Elect Director: Robert Alan Beardsley”): 124,837,983 for, 5,277,874 withheld, per its Form 8-K filed 2025-05-23 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 191,527,129 outstanding shares: 65% for, 3% withheld (68% of the company cast a for/withheld vote).

The 36 asset managers below cast 100% of the shares they voted on this item FOR (27,883,253 for, 0 against).

FOR 100%
FOR: 27,883,253 (100.0%)
Largest asset managers voting on “To elect five (5) director nominees named in the Proxy Statement/Circular, each to serve until the 2026 Annual” at ARBUTUS BIOPHARMA CORP., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard8,631,0060 00For
Morgan Stanley6,930,2430 00For
BlackRock5,196,3830 00For
Fidelity2,236,8420 00For
Equitable1,452,5240 00For
Charles Schwab1,196,1920 00For
State Street643,5800 00For
Aberdeen342,3790 00For
TIAA311,1730 00For
Lincoln Financial195,5760 00For
Global X87,2170 00For
Goldman Sachs76,1520 00For
Northern Trust75,3330 00For
ProShares59,3470 00For
John Hancock55,6370 00For
Pacific Life48,2210 00For
ETFis Series Trust I43,2090 00For
Voya40,7200 00For
Invesco34,9970 00For
Direxion Shares ETF Trust32,5530 00For
Bridge Builder Trust32,1230 00For
DWS21,1530 00For
QUANTITATIVE MASTER SERIES LLC21,0610 00For
Nationwide21,0490 00For
Columbia Threadneedle17,8010 00For

Showing the 25 largest of 36 asset managers. See all 36 in the interactive database.

8. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

99% fund support · no official result

FOR 98%

The 4 asset managers below cast 99% of the shares they voted on this item FOR (2,571,309 for, 38,513 against).

FOR: 2,571,309 (98.5%)AGAINST: 38,513 (1.5%)ABSTAIN: 1,589 (0.1%)
Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at ARBUTUS BIOPHARMA CORP., 2024-2025
Asset managerForAgainst AbstainWithheldVote
ADAGE CAPITAL PARTNERS GP, L.L.C.1,575,9410 00For
Saba Capital Management, L.P.925,41631,768 1,5890For
JPMorgan69,9520 00For
Desjardins Global Asset Management Inc.06,745 00Against

9. DIRECTOR

DIRECTOR ELECTIONS

100% fund support · no official result

FOR 91%9%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (1,487,765 for, 0 against).

FOR: 1,487,765 (90.8%)ABSTAIN: 151,110 (9.2%)
Largest asset managers voting on “DIRECTOR” at ARBUTUS BIOPHARMA CORP., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Saba Capital Income & Opportunities Fund952,5910 96,7540For
Saba Capital Income & Opportunities Fund II535,1740 54,3560For

Largest ARBUTUS BIOPHARMA CORP. shareholders voting in 2024-2025

Ranked by the number of ARBUTUS BIOPHARMA CORP. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 191,527,129 shares outstanding at the time of that meeting.

Top ARBUTUS BIOPHARMA CORP. shareholders by shares voted, 2024-2025
#Asset manager % of shares outstanding
1Morgan Stanley 15.17%
2Two Seas Capital LP 4.84%
3Vanguard 4.76%
4BlackRock 4.46%
5State Street 1.46%
6Woodline Partners LP 1.33%
7Charles Schwab 1.25%
8Fidelity 1.18%
9GEODE CAPITAL MANAGEMENT, LLC 1.15%
10Equitable 0.76%

Reported ARBUTUS BIOPHARMA CORP. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

ARBUTUS BIOPHARMA CORP. beneficial owners on record for the 2024-2025 proxy season
Holder % outstanding Disclosure
Matthew Gline 20.28% DEF14A
Roivant Sciences Ltd. 20.28% 13D
Morgan Stanley 13.53% 13G
Two Seas Capital LP 9.69% 13G
Whitefort Capital Master Fund, LP 8.25% 13D
Whitefort Capital Management, LP 6.95% DEF14A
BlackRock 6.67% 13F
Vanguard Group 4.67% 13F
State Street 2.28% 13F
Michael J. McElhaugh 1.38% DEF14A

Percentages above are of 191,527,129 shares outstanding, as reported by ARBUTUS BIOPHARMA CORP. on its Form 10-Q dated 2025-05-12 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ARBUTUS BIOPHARMA CORP.’s 10-Q dated 2025-05-12. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At ARBUTUS BIOPHARMA CORP.'s shareholder meeting held 2025-05-21, in the 2024-2025 proxy season, 137 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,038 separate fund positions. Their filings are grouped here into 9 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. ARBUTUS BIOPHARMA CORP.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, on a non-binding advisory basis, the compensation of our named executive officers… — the reporting funds cast 98% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

ARBUTUS BIOPHARMA CORP. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.